SynthesisJournal of cachexia, sarcopenia and muscle2024
Sarcopenic obesity and health outcomes: An umbrella review of systematic reviews with meta-analysis.
Synthesis in Journal of cachexia, sarcopenia and muscle, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Persevering or quitting? A systematic review of adherence and dropout in nutrition and exercise interventions for sarcopenic obesity.Asia Pacific journal of clinical nutrition · 2026Pooled it
- Exercise-based interventions for sarcopenic obesity in middle-aged and older adults: an umbrella review of systematic reviews with pairwise meta-analyses and network meta-analyses.Frontiers in nutrition · 2026Pooled it
- The association of ultra-processed food intake on age-related muscle conditions: a systematic review and dose-response meta-analysis with meta-regression.Journal of health, population, and nutrition · 2025Pooled it
- Biomarkers for sarcopenia, muscle mass, muscle strength, and physical performance: an umbrella review.Journal of translational medicine · 2025Pooled it
- Sarcopenic obesity and health outcomes: An umbrella review of systematic reviews with meta-analysis.Journal of cachexia, sarcopenia and muscle · 2024Pooled it
- Age- and Sex-Specific Percentile Curves for the FM/FFM Ratio Using Data From the Canadian Longitudinal Study on Aging.Journal of cachexia, sarcopenia and muscle · 2026Article
- CT-Quantified Sarcopenic Visceral Obesity Is Negatively Associated with Recompensation in Patients with Decompensated Cirrhosis: A Retrospective Single-Center Study.Journal of clinical medicine · 2026Article
- Clinical characteristics and survival in sarcopenic obesity defined by the Japanese working group on sarcopenic obesity criteria versus existing definitions in older adults: findings from the Otassha study.International journal of obesity (2005) · 2026Article
- Evaluation of Sarcopenic Obesity in Patients with MASLD.Medical sciences (Basel, Switzerland) · 2026Article
- The Effect of Cranberry Consumption on Body Weight and Liver Enzymes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Food science & nutrition · 2026Review
- Overview of rehabilitation interventions for ESPEN/EASO-defined sarcopenic obesity: a scoping review.European geriatric medicine · 2026Article
- Comparative analysis of sarcopenic obesity detection and associated mental-cognitive outcomes in community-dwelling older adults: impact of using body mass index versus waist circumference.BMC geriatrics · 2026Article
- Exercise Improves Sarcopenic Obesity Through Inhibition of Ferroptosis and Activation of the AMPK/ACC Pathway.International journal of molecular sciences · 2026Article
- Optimizing prescription of resistance training for body composition, muscle strength, and physical performance in older adults with sarcopenia: a systematic review and meta-analysis.European review of aging and physical activity : official journal of the European Group for Research into Elderly and Physical Activity · 2026Review
- Composite dietary fiber alleviates obesity-induced skeletal muscle atrophy by regulating gut microbiota-derived short-chain fatty acids in mice.NPJ science of food · 2026Article
- Obesity-induced metabolic reprogramming of the tumor immune microenvironment: mechanisms, spatial niches, and immunotherapy response.Frontiers in immunology · 2026Review
- The Role of hs-CRP and Systemic Immune-Inflammation Index in Sarcopenia and Sarcopenic Obesity in Young Populations: Results from the National Health and Nutrition Examination Survey 2015-2018.Endocrine, metabolic & immune disorders drug targets · 2026Article
- Nutrition Patterns, Metabolic and Psychological State Among High-Weight Young Adults: A Network Approach.Nutrients · 2026Article
- Association and predictive value of sarcopenic obesity for the prognosis of lung cancer patients receiving immune checkpoint inhibitors.Frontiers in nutrition · 2026Article
- Adipose-muscle crosstalk during the menopausal transition: mechanistic links to sarcopenic obesity in midlife women.Frontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many studies support the idea that sarcopenic obesity (SO) could be considered a potential risk factor for negative health outcomes. These results have been inconsistent, and no umbrella reviews exist regarding this topic. Several databases until November 2023 were searched for systematic reviews with meta-analysis of observational studies (cross-sectional, case-control and prospective). For each association, random-effects summary effect sizes with correspondent 95% confidence intervals (CIs) were evaluated using the GRADE tool. Among the 213 papers initially screened, nine systematic reviews with meta-analysis were included, for a total of 384 710 participants. In cross-sectional and case-control studies, 30 different outcomes were analysed, and 18 were statistically significant. In any population addressed in cross-sectional and case-control studies, compared with non-SO, SO increased the prevalence of cognitive impairment (k = 3; odds ratio [OR] = 3.46; 95% CI: 2.24-5.32; high certainty of evidence), coronary artery disease (k = 2; OR = 2.48; 95% CI: 1.85-3.31) and dyslipidaemia (k = 3; OR = 2.50; 95% CI: 1.51-4.15). When compared with sarcopenia or obesity, the results were conflicting. In prospective studies, the association between SO-compared with non-SO-and other negative outcomes was supported by low/very low certainty of evidence and limited to a few conditions. Besides, no comparison with sarcopenia or obesity was provided. Finally, only a few studies have considered muscle function/physical performance in the diagnostic workup. SO could be considered a risk factor only for a few conditions, with the literature mainly based on cross-sectional and case-control studies. Future studies with clear definitions of SO are needed for quantifying the importance of SO-particularly when compared with the presence of only sarcopenia or obesity-and the weight of muscle function/physical performance in its definition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.